Sodium oxybate for the treatment of narcolepsy

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin reuptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.

Original languageEnglish (US)
Pages (from-to)329-335
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number2
StatePublished - Feb 1 2005


  • Cataplexy
  • Gamma-hydroxybutyrate
  • Narcolepsy
  • Pharmacotherapy
  • Sodium oxybate

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sodium oxybate for the treatment of narcolepsy'. Together they form a unique fingerprint.

Cite this